The DDR-immune fitness score: a biomarker for guiding parp and immunotherapy synergy in extensive-stage small cell lung cancer
{{output}}
Background: Despite the integration of PD-L1 inhibitors with chemotherapy, extensive-stage small-cell lung cancer (ES-SCLC) continues to portend a dismal prognosis, with a 5-year survival rate below 10%. A critical unmet need is ... ...
